SciVision Biotech Inc. (TPE:1786)
Taiwan
· Delayed Price · Currency is TWD 66.00
-4.10 (-5.85%)
Mar 9, 2026, 1:35 PM CST
SciVision Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 886.62 | 883.31 | 712.99 | 557.35 | 505.54 | Upgrade
|
| Revenue Growth (YoY) | 0.38% | 23.89% | 27.93% | 10.25% | 8.28% | Upgrade
|
| Cost of Revenue | 248.23 | 227.63 | 200.49 | 185.48 | 163.7 | Upgrade
|
| Gross Profit | 638.39 | 655.68 | 512.49 | 371.87 | 341.84 | Upgrade
|
| Selling, General & Admin | 355.28 | 346.86 | 259.44 | 184.8 | 153.95 | Upgrade
|
| Research & Development | 93.19 | 60.71 | 53.42 | 52.46 | 65.94 | Upgrade
|
| Operating Expenses | 448.47 | 407.57 | 312.86 | 237.26 | 219.89 | Upgrade
|
| Operating Income | 189.92 | 248.11 | 199.64 | 134.61 | 121.94 | Upgrade
|
| Interest Expense | -7.93 | -5.67 | -8.22 | -6.46 | -8.07 | Upgrade
|
| Interest & Investment Income | 24.42 | 20.61 | 14.9 | 4.88 | 2.63 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 20.48 | -0.51 | 11.81 | -1.46 | Upgrade
|
| Other Non Operating Income (Expenses) | -21.37 | 1.43 | 0.75 | 0.17 | 1.01 | Upgrade
|
| EBT Excluding Unusual Items | 185.04 | 284.96 | 206.56 | 145.02 | 116.05 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 6.45 | 2.9 | -1.98 | -0.13 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.19 | 0.54 | 30.55 | 0.13 | Upgrade
|
| Other Unusual Items | - | - | - | -0.04 | - | Upgrade
|
| Pretax Income | 185.04 | 291.6 | 210 | 173.55 | 116.06 | Upgrade
|
| Income Tax Expense | 22.7 | 49.34 | 32.1 | 31.83 | 14.34 | Upgrade
|
| Net Income | 162.34 | 242.25 | 177.9 | 141.72 | 101.72 | Upgrade
|
| Net Income to Common | 162.34 | 242.25 | 177.9 | 141.72 | 101.72 | Upgrade
|
| Net Income Growth | -32.99% | 36.17% | 25.53% | 39.32% | -20.53% | Upgrade
|
| Shares Outstanding (Basic) | 72 | 69 | 67 | 66 | 66 | Upgrade
|
| Shares Outstanding (Diluted) | 74 | 74 | 76 | 75 | 71 | Upgrade
|
| Shares Change (YoY) | -0.00% | -2.58% | 2.39% | 5.18% | 0.61% | Upgrade
|
| EPS (Basic) | 2.24 | 3.51 | 2.66 | 2.14 | 1.54 | Upgrade
|
| EPS (Diluted) | 2.18 | 3.30 | 2.41 | 1.92 | 1.51 | Upgrade
|
| EPS Growth | -33.98% | 37.15% | 25.26% | 27.30% | -20.11% | Upgrade
|
| Free Cash Flow | 22.46 | 235.11 | 257.28 | 167.03 | 72.73 | Upgrade
|
| Free Cash Flow Per Share | 0.30 | 3.16 | 3.37 | 2.24 | 1.02 | Upgrade
|
| Dividend Per Share | - | 3.250 | 2.500 | 2.000 | 1.420 | Upgrade
|
| Dividend Growth | - | 30.00% | 25.00% | 40.84% | 60.49% | Upgrade
|
| Gross Margin | 72.00% | 74.23% | 71.88% | 66.72% | 67.62% | Upgrade
|
| Operating Margin | 21.42% | 28.09% | 28.00% | 24.15% | 24.12% | Upgrade
|
| Profit Margin | 18.31% | 27.43% | 24.95% | 25.43% | 20.12% | Upgrade
|
| Free Cash Flow Margin | 2.53% | 26.62% | 36.08% | 29.97% | 14.39% | Upgrade
|
| EBITDA | 270.35 | 310.17 | 261.42 | 195.35 | 173.08 | Upgrade
|
| EBITDA Margin | 30.49% | 35.12% | 36.66% | 35.05% | 34.24% | Upgrade
|
| D&A For EBITDA | 80.43 | 62.06 | 61.78 | 60.74 | 51.14 | Upgrade
|
| EBIT | 189.92 | 248.11 | 199.64 | 134.61 | 121.94 | Upgrade
|
| EBIT Margin | 21.42% | 28.09% | 28.00% | 24.15% | 24.12% | Upgrade
|
| Effective Tax Rate | 12.27% | 16.92% | 15.29% | 18.34% | 12.35% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.